Doctors save leg by removing 50-cm blood clot in rare surgery
Doctors save leg by removing 50-cm blood clot in rare surgery
Doctors save leg by removing 50-cm blood clot in rare surgery
A medical team in Kuzbass has performed a rare and life-saving procedure. Doctors removed a 50-centimetre blood clot from a patient's leg, preventing a likely amputation. The man had been admitted in critical condition with severe circulation issues and intense pain.
The patient arrived at the hospital suffering from deep vein thrombosis caused by atherosclerosis. His right leg was at serious risk due to blocked blood flow, leaving doctors with little time to act. Without intervention, amputation would have been unavoidable.
Surgeons worked to extract the massive clot, which stretched half a metre in length. The operation succeeded, restoring proper circulation and saving the leg. Medical staff confirmed the patient's condition stabilised after the procedure.
The successful removal of the clot has spared the man from losing his limb. Recovery will require further monitoring, but the immediate threat has passed. This case highlights the severity of untreated vascular conditions and the importance of timely medical intervention.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?